These effects on HDL phenotype should increase the risk for atherosclerosis (Sirtori et al., 2001), but actually atherosclerotic lesions in patients with CAD regressed when apoA-IMilano was administered intravenously (Nissen et al., 2003). This evidence concerns the gene APOA1 and coronary artery disorder.